



Worldwide Biopharmaceutical Businesses

Mr Tim Irish
Appeals Committee Vice Chair
National Institute for Health & Care Excellence
10 Spring Gardens
LONDON
SW1A 2BU

10th December 2020

Dear Mr Irish

Appeal against the Final Appraisal Determination for Tafamidis for Treating Transthyretin Amyloidosis with Cardiomyopathy

Thank you for your letter dated 30 November 2020, in which you provide your final decision on the admissibility of the points of appeal set out in Pfizer's appeal document submitted on 30 October 2020, and in our response to your Initial Scrutiny letter dated 23 November 2020.

Please note that ground 2, appeal point 2.8 was confirmed as a valid appeal point in your Initial Scrutiny letter but has been inadvertently omitted from the list of valid appeal points in your Final Scrutiny Letter.

We understand that your decision on the admissibility of the points of appeal is final. However, we believe that the time to apply for judicial review would not start to run until the decision of the Appeal Panel has been communicated to us, and this applies in the context of all appeal points, including appeal points that are not permitted to proceed to hearing. If NICE disagrees, we should be grateful if you would notify us accordingly.

Yours sincerely

, Pfizer UK